Log in
Enquire now
‌

US Patent 10336824 Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof

Patent 10336824 was granted and assigned to CytomX Therapeutics on July, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
CytomX Therapeutics
CytomX Therapeutics
0
Current Assignee
CytomX Therapeutics
CytomX Therapeutics
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
103368240
Patent Inventor Names
Stephen James Moore0
Daniel Robert Hostetter0
James William West0
Jason Gary Sagert0
Li Mei0
Margaret T. L. Nguyen0
Olga Vasiljeva0
Jonathan Alexander Terrett0
Date of Patent
July 2, 2019
0
Patent Application Number
150696220
Date Filed
March 14, 2016
0
Patent Citations
‌
US Patent 10011656 Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
‌
US Patent 10081679 Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy
‌
US Patent 10072082 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
0
Patent Citations Received
0
‌
US Patent 11548944 Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
0
‌
US Patent 10669339 Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
‌
US Patent 11548943 Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
0
‌
US Patent 11028126 Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
‌
US Patent 11046759 Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
‌
US Patent 11884746 Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
0
‌
US Patent 11472875 Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
Patent Primary Examiner
‌
Misook Yu
0
Patent abstract

The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10336824 Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.